Document:

EX-10.2

 EXHIBIT 10.2

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN FOR JAMES A. YOST

     This Supplemental Executive Retirement Plan (the “Plan”) for James A. Yost is effective as of
the later of the date employment commences with Dana Holding Corporation (the “Company”) or May 1,
2008 (the “Effective Date”), in order to provide James A. Yost (the “Participant”) with certain
additional, non-qualified retirement benefits. The provisions of this Plan shall apply only to the
Participant.

ARTICLE I

DEFINITIONS

     “Cause” means:

     A. Any act or omission constituting a material breach by the Executive of any provisions of the
Employment Agreement ( as defined below) that has not been cured within thirty (30) days after
written notice to the Executive describing the breach and the nature of the conduct necessary
to cure the breach;

     B. The willful failure by the Executive to perform his duties hereunder (other than any such
failure resulting from the Executive’s Disability), after demand for performance is delivered
by Company that identifies in reasonable detail the manner in which Company believes the
Executive has not performed his duties, if, within 30 calendar days of such demand, the
Executive fails to cure any such failure capable of being cured;

     C. Any intentional act or misconduct materially injurious to Company or any Subsidiary,
financial or otherwise, or any act of misappropriation, fraud including with respect to
Company’s accounting and financial statements, embezzlement or conversion by the Executive of
Company’s or any of its Subsidiary’s property;

     D. The conviction (or plea of no contest) of the Executive for any felony including any felony
involving fraud, moral turpitude, embezzlement or theft;

     E. The commission of any violation of any antifraud provision of federal or state securities
laws; or

     F. Alcohol or prescription or other drug abuse substantially affecting work performance.

          “Code” means the Internal Revenue code of 1986, as from time to time amended.

1

 

     “Committee” means the Chief Administrative Officer, the Vice President, General
Counsel and Secretary, and the Director of Compensation of the Company. If any of the Committee
members would have a personal interest in the discharge of the duties of the Committee, that
individual must recuse himself or herself from the decisions of the Committee.

     “Company” means Dana Holding Corporation, a Delaware Corporation.

     “Disability” or “Disabled” will mean the Executive’s incapacity due to physical or
mental illness to substantially perform his duties and the essential functions of his position,
with or without reasonable accommodation, on a full-time basis for six months as determined by the
Board in its reasonable discretion, and within 30 days after a notice of termination is thereafter
given by the Company, the Executive will not have returned to the full-time performance of the
Executive’s duties; provided, however, if the Executive disputes a determination to
terminate his employment because of Disability, the question of the Executive’s disability will be
subject to the certification of a qualified medical doctor selected by the Company and the
Executive. The costs of such qualified medical doctor will be paid for by the Company.

     “Employment Agreement” means the agreement of employment between Company and
Participant of even date herewith.

     “Good Reason” means (i) a reduction in the Executive’s Base Salary or benefits (other than
reductions applied similarly to all of the Company’s senior executives); (ii) failure to pay or
provide any of the compensation set forth in this Agreement (except for reductions applied
similarly to all of the Company’s senior executives); (iii) a material adverse change by the
Company in the Executive’s title, position, authority or reporting relationships within the Company
(and which shall not include any additional duties assigned to the Executive based on his past
experience and background); and (iv) a failure by the Company to comply with any material provision
of this Agreement, which failure is not cured (if capable of cure) within 15 days (or in any event
after 45 days if not

2

 

capable of cure within 15 days) after written notice of such non-compliance by
the Company.

     “Normal Retirement Date” means the last day of the 36th month of the
Participant’s employment with the Company.

     “Normal Retirement Benefit” means the lump sum benefit payable to the Participant as
set forth in Section 2.1 of the Plan upon attainment of the Normal Retirement Date.

     “Participant” means James A. Yost

     “Plan” means the Supplemental Executive Retirement Plan for James Yost set forth
herein.

     “SavingsWorks” means the Company-sponsored 401(k) defined contribution plan.

     “Termination Date” means the date on which the Participant ceases to be employed by
the Company for any reason, including, but not limited to, by reason of his death, disability or
his election to retire or voluntarily resign.

ARTICLE II

BENEFITS

     2.1 Normal Retirement Benefit. If employment continues to at least the Participant’s
Normal Retirement Date, the Company shall be obligated to pay the Participant upon the
Participant’s Termination Date in a single lump sum, the Participant’s the Normal Retirement
Benefit. The Participant’s Normal Retirement Benefit shall equal the accumulated balance in a
notional defined contribution account (the “SERP account”). The Company shall credit the SERP
account each year in the following manner:

3

 

	 	(a)	 	Twenty percent (20%) of the Participant’s base salary amount paid by the
Company; plus
	 
	 	(b)	 	Twenty percent (20%) of the Participant’s gross award under the Dana Holding
Company Annual Incentive Plan, as may be amended and restated from time to time (the
“Incentive Plan”); minus
	 
	 	(c)	 	The amount credited to the Participant under SavingsWorks without regard to
any matching contributions.

On the first day of each calendar year, the Company shall credit to the SERP account the amount
described in paragraph (a) of this Section based on the base salary earned by the Participant in
the preceding calendar year. For this purpose, base salary means the gross amount payable to the
Participant without regard to reductions such as employment tax withholdings or additions such as
imputed income amounts.

With respect to the amount described in paragraph (b) of this Section, the Company shall credit the
amount specified in paragraph (b) above on the day the Incentive Plan award is paid by the
Company. The Company shall, on an annual basis, provide the Participant with a statement which
shows the balance accrued in the SERP, including the amounts described in Section 2.2, below.

     2.2 Earnings Credit. On the first day of each calendar year an earnings credit shall
be added to the SERP account. Such earnings credit shall equal five percent (5%) of the balance in
the SERP account as of the end of the preceding calendar year except that the earnings credit on
the portion of the SERP account that is attributable to the Participant’s receipt of an Incentive
Award in such preceding year shall be pro-rated based on an annualized return of five percent (5%).

     2.3 Vesting Conditions. Except as expressly provided in Section 2.4 below, the Normal
Retirement Benefit shall be forfeited if the Participant’s Termination Date occurs before the date
the Participant attains Normal Retirement Date (the “Vesting Date”).

4

 

     2.4 Involuntary Termination; Disability; Death. If, prior to his Normal Retirement
Date, the Participant’s employment with the Company terminates as a result of the Participant’s:
(a) death or Disability; (b) involuntary termination by the Company for a reason other than Cause;
or (c) resignation for Good Reason, the SERP account to which the Participant is entitled under
this Agreement shall immediately vest and the Company shall credit the SERP account in the manner
specified in section 2.1 with respect to any base salary or Incentive Award earned or paid in the
year of termination but only to the extent the SERP account had not previously credited such base
salary or Incentive Award. Any benefit payable pursuant to this Section 2.4 shall be paid in cash
in a single lump sum.

     2.5 Termination. For purposes of this Plan, no payment that would otherwise be made
and no benefit that would otherwise be provided upon a termination of employment will be made or
provided unless and until such termination of employment is also a “Separation from Service” (as
determined in accordance with Section 409A of the Code).

     2.6 Beneficiary. In the event of the Participant’s death, the Participant’s
beneficiary under SavingsWorks shall be entitled to receive any benefits that otherwise would have
been payable to the Participant hereunder. In the event the Participant has not designated a
beneficiary under SavingsWorks, the Participant’s estate shall be entitled to receive any benefits
that otherwise would have been payable to the Participant hereunder.

     2.7 Section 409A Delay. Notwithstanding any provisions of Section 2 to the contrary,
if the Participant is a “specified employee” (within the meaning of Section 409A and determined
pursuant to procedures adopted by the Company) at the time of his Separation from Service and if
any portion of the payments or benefits to be received by the Participant under Section 2 upon his
separation of service with the Company would be considered deferred compensation under
Section 409A, then the following provisions will apply to the relevant portion:

5

 

	 	A.	 	Each portion of such payments and benefits that would otherwise be payable
pursuant to Section 2 during the six-month period immediately following the
Participant’s Separation of Service (the “Delayed Period”) will instead be paid or
made available on the earlier of (i) the first business day of the seventh month
following the date the Participant incurs a Separation of Service; and (ii) the
Participant’s death (the applicable date, the “Permissible Payment Date”);
	 
	 	B.	 	Payments delayed under Section 2.7 as a result of the application of Section
409A will not accrue interest. In no event will the reimbursements or in-kind
benefits to be provided by the Company in one taxable year affect the amount of
reimbursements or in-kind benefits to be provided in any other taxable year, nor will
the Participant’s right to reimbursement or in-kind benefits be subject to liquidation
or exchange for another benefit; and
	 
	 	C.	 	Each payment under this Plan will be considered a “separate payment” and not
of a series of payments for purposes of Section 409A.

ARTICLE III

PLAN ADMINISTRATION

     3.1 Administration of Plan. The Committee shall have the sole responsibility for the
administration of the Plan.

     3.2 Claims Procedure. The Committee shall make all determinations as to the right of
any person to a benefit under this Plan and the amount of such benefit. Any denial by the
Committee of a claim for benefits under the Plan by Participant shall be stated in writing by the
Committee and shall set forth the specific reasons for the denial. In addition, the Committee
shall afford a reasonable opportunity to any Participant whose claim for benefits has been denied
for a review of the decision denying the claim. The Participant may, in such circumstances, invoke
the provisions of Section 17 of the Employment Agreement and submit the dispute to arbitration.

     3.3 Powers and Duties of the Committee. The Committee shall have such duties and
powers as may be necessary to discharge its duties hereunder, including, but not by way of
limitation, the following:

6

 

	 	(a)	 	to construe and interpret the Plan, to resolve ambiguities, inconsistencies,
and omissions and determine the amount, manner and time of payment of any benefits
hereunder. In the event of any disagreement regarding interpretation of the Plan, the
Participant may, in such circumstances, invoke the provisions of Section 17 of the
Employment Agreement and submit the dispute to arbitration.
	 
	 	(b)	 	to prescribe procedures to be followed by Participant in filing elections or
revocations thereof;
	 
	 	(c)	 	to prepare and distribute, in such manner as the Committee determines to be
appropriate, information explaining the Plan, including an annual statement of account
to Participant;
	 
	 	(d)	 	to receive for the Company and from Participant such information as shall be
necessary for the proper administration of the Plan;
	 
	 	(e)	 	to furnish the Company, upon request, such reports with respect to the
administration of the Plan as are reasonable and appropriate;
	 
	 	(f)	 	to appoint individuals to assist in the administration of the Plan and any
other agents it deems advisable, including actuaries and legal counsel; and
	 
	 	(g)	 	to create subcommittees and appoint agents, and to delegate such of its
rights, powers and discretions to such subcommittees or agents as it deems desirable.

     3.4 Rules and Decisions. The Committee may adopt such rules as it deems necessary,
desirable or appropriate for the proper administration of the Plan. When making a determination or
calculation, the Committee shall be entitled to rely upon information furnished by a Participant or
the Company. In the event the Participant disputes the Committee’s determination or calculations,
the determination of the Committee as to any question involving the administration and
interpretation of the Plan shall be subject to arbitration pursuant to the provisions of Section 17
of the Employment Agreement.

     3.5 Indemnification of Committee. To the extent permitted by law, the Committee and
any person to whom it may delegate any duty or power in connection with administering the Plan, the
Company, and the officers and trustees thereof, shall be entitled to rely conclusively upon, and
shall be fully protected in any action taken or suffered by them in good faith in reliance upon,
any actuary, trustee, counsel, accountant,

7

 

other specialist, or other person selected by the
Committee, or in reliance upon any tables, valuations, certificates, opinions or reports that may
be furnished by any of them. Further, to the extent permitted by law, no member of the Committee,
nor the Company, nor the officers or trustees thereof, shall be liable for any neglect, omission or
wrongdoing, except for his, her or its own individual misconduct. To the extent permitted by law,
any present or former member of the Committee shall be indemnified by the Company and its
successors against any and all liabilities arising; by reason of any act or failure to act made in
good faith pursuant to the provisions of the Plan, including expenses reasonably incurred in the
defense of any claim relating thereto.

ARTICLE IV

MISCELLANEOUS

     4.1 Withholding of Taxes. The Company may deduct or withhold from any payments to be
made under the Plan any Federal, state, local income or employment taxes as required under
applicable laws to be withheld (including under Code Section 409A), or may instead require the
Participant or Beneficiary, as the case may be, to pay any such amount, or the balance of any such
amount.

     4.2 No Contract of Employment. Nothing contained herein shall be construed as a
contract of employment between the Company and Participant, or as giving a right to Participant to
be continued as an executive or employee of the Company, or as a limitation of the right of the
Company to discharge Participant at any time with or without Cause. The parties acknowledge the
Employment Agreement as it relates to the obligations of each of the parties.

     4.3 Addresses. Each person entitled to benefits hereunder shall file with the
Committee from time to time in writing his or her complete mailing address and each change of
mailing address. Any check representing payment hereunder, and any communication, addressed to
Participant or to any other person at his or her last address so filed (or if no such address has
been filed, then at his or her last address indicated on

8

 

the records of the Company) shall be
deemed to have been received by such person for all purposes of the Plan, and neither the Company
nor any other person shall be obligated to search for or ascertain the location of any such person
to whom such communication was sent.

     4.4 Expenses. All expenses that shall arise in connection with the administration of
the Plan, including but not limited to compensation and other expenses and charges of any actuary,
trustee, counsel, accountant, specialist, or other person who shall be employed by the Committee in
connection with the administration thereof, shall be paid by the Company.

     4.5 Anti-Alienation. Except as may otherwise be provided by law, no distribution or
payment under the Plan to any Participant or beneficiary shall be subject in any manner to
anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge, whether
voluntary or involuntary, and any attempt to anticipate, alienate, sell, transfer, assign, pledge,
encumber or charge the same shall be void; nor shall any such distribution or payment be in any way
liable for or subject to the debts, contracts, liabilities, engagements or torts of any person
entitled to such distribution or payment.

     4.6 Unfunded Plan. The benefits payable under the Plan shall be paid from the general
assets of the Company. Participant and his beneficiary shall not have any interest in any specific
assets of the Company by reason of the establishment and maintenance of the Plan, and such persons
shall have only the status of unsecured creditors of the Company with respect to any benefits that
become payable under the Plan. The Company may, in its discretion, purchase insurance contracts or
establish a trust to assist it in satisfying its obligations to provide benefits under the Plan;
provided, however, that (i) any such insurance contracts and the assets of any such trust shall
remain subject to the claims of the Company’s general creditors in the event of the Company’s
insolvency, (ii) the Company or such trust shall be the sole owner of any such insurance contracts,
and (iii) no Participant or any other person who may become entitled to benefits hereunder shall
have any interest in any such insurance contract.

9

 

     4.7  Compliance with Code Section 409A. It is intended that any amounts payable under
this Plan and the Company’s and the Participant’s exercise of authority or discretion hereunder
will comply with the provisions of Section 409A of the Code and the treasury regulations relating
thereto so as not to subject the Participant to the payment of the additional tax, interest and any
tax penalty which may be imposed under Code Section 409A. Reference to Section 409A of the Code is
to Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any
proposed, temporary or final regulations, or any other guidance, promulgated with respect to such
Section by the U.S. Department of Treasury or the Internal Revenue Service. Notwithstanding the
foregoing, no particular tax result for the Participant with respect to any income recognized by
the Participant in connection with the Plan is guaranteed, and the Participant will be responsible
for any taxes, penalties and interest imposed on him under or as a result of Section 409A of the
Code in connection with the Plan.

     4.8 Incompetency. If the Committee determines that any person entitled to payments
under the Plan is an infant or incompetent by reason of physical or mental disability, it may cause
all payments thereafter becoming due to such person to be made to any other person for his or her
benefit, without the responsibility to follow the application of amounts so paid. Payments made
pursuant to this provision shall completely discharge the Plan and the Committee from any further
liability or responsibility therefor.

     4.9 Benefits Not Compensation. Any benefits provided under the Plan shall not be
deemed salary or other compensation to the Participant for the purpose of computing any benefits to
which the Participant may be entitled under any pension plan or other employee benefit plan
maintained by the Company.

     4.10 Amendment or Termination of Plan. The Company may not amend or terminate this
Plan without the written consent of Participant or, after Participant’s Death or Disability, any
beneficiary.

10

 

     4.11 Ohio Law to Govern. This Plan shall be construed and regulated and its validity
and effect and the rights hereunder of all parties interested shall at all times be determined and
this Plan shall be administered, in accordance with the laws of the State of Ohio.

     4.12 Successors and Assigns. This Plan shall be binding upon and shall inure to the
benefit of the Participant and his heirs, executors, administrators and beneficiaries, and shall be
binding upon and inure to the benefit of the Company (and its parent, if any, and affiliates) and
its successors and assigns.

     4.13 Entire Agreement. This Plan constitutes the final, complete and exclusive
agreement between Participant and the Company with respect to the subject matter hereof and hereby
replaces and supercedes all prior agreements, offers or promises whether oral or written with
respect thereto. In the event of any inconsistency between this Agreement and any other agreement
which binds or benefits the Executive and the Company, this Agreement shall govern and control.

DANA HOLDING CORPORATION

By:  /s/ Robert H. Marcin                                        

Name: Robert H. Marcin

Title: Chief Administrative Officer

			
	ACCEPTED AND AGREED:	 	 /s/ James A. Yost                                        

JAMES A. YOST

11ex4_57.htm

    Exhibit 4.57

     

     

    
      	 Amarin
      694/005	 	 
	 	 	 
	 Protocol
      AN01.01.0012	 	
               Change Order
      no. 2, 8th June 2006

            

    

     

     

    Change
Order

     

    
      	
              DATED

            	
              the
      8th day of June 2006.

            

    

     

    
      	
              BETWEEN

            	
              Amarin
      Neuroscience Limited of King’s Park House, Laurelhill Business Park,
      Stirling, UK FK7 9PQ (‘Amarin’)

            

    

     

    
      	
              AND

            	
              ICON
      Clinical Research Limited of South County Business Park, Leopardstown,
      Dublin 18 (‘ICON’)

            

    

     

     

    WHEREAS:

     

    
      	
              A.

            	
              The
      parties entered into an Agreement for Services on 30th June 2005,
      concerning Study known as Protocol AN01.01.0012A Multi-centre,
      double-blind, randomized, parallel group, placebo-controlled trial of
      ethylepa (Ethyl-Icosapent) in patients with Huntington’s
      Disease.  This is a Europe only
study.

            

    

     

    
      	
              B.

            	
              The
      main changes to the project specifications are to the study timelines, the
      site and patient distribution and the CRF page numbers.  The
      revised specifications are detailed in Appendix 1
  attached.

            

    

     

     

    IT
IS AGREED BY THE PARTIES AS FOLLOWS:

     

    
      	
               
      

            	
              1.

            	
              The
      parties agree to amend the Agreement to reflect changes set out in the
      ‘European Revised Project Specifications and Cost Document’ which is
      attached hereto and incorporated
hereby.

            

    

     

    
      	
               
      

            	
              2.

            	
              Save
      as otherwise provided in this Change Order, all the terms and conditions
      of the Agreement dated the 30th June 2005 shall remain in full force and
      effect.

            

    

     

    
      	
               
      

            	
              3.

            	
              The
      value of this Change Order shall be £382,057 in direct fees and £1,385,655
      in pass through costs.  The direct fees shall be paid in an
      initial fee of 10% at signature of this agreement and monthly fees
      thereafter as outlined below:

            

    

     

    
      	Change
      Order Direct Fee Value:	£382,057 
	
              Initial
      Payment 10% on siqnature of Change Order (June 06)

            	
                £38,205

            
	
              Monthly
      Payments x 12 months (June’06 to May’07)

            	
              £28,654.33

            

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      694/005	 	 
	 	 	 
	 Protocol
      AN01.01.0012	 	
                 Change Order
      no. 2, 8th June 2006

              

      

       

    IN WITNESS WHEREOF, the
parties hereto have executed this Change Order by their duly authorised
representatives on the date(s) written below.

     

    
      	
              Amarin
      Neuroscience Limited

            	
              ICON
      Clinical Research Limited

            
	
              King’s
      Park House

            	
              South
      County Business Park

            
	
              Laurelhill
      Business Park

            	
              Leopardstown

            
	
              UKFK7
      9PQ

            	
              Dublin
      18

            
	
              United
      Kingdom

            	
              Ireland

            

    

    

    
 

    
      
        	 30
      June 2006	 	 29
      September 2006
	
                DATE

              	 
      	
                DATE

              
	 	 	 
	 /s/
      Anthony Clarke	 	 /s/
      Sean Leech
	
                SIGNED

              	 
      	
                SIGNED

              
	 	 	 
	 A.
      CLARKE	 	 SEAN
      LEECH
	
                NAME

              	 
      	
                NAME

              
	 	 	 
	
                 

                 V.P.
      CLINICAL DEVELOPMENT

              	 	 EXEC.
      VP COMMERCIAL AND ORGANISATIONAL DEVELOPMENT
	
                TITLE

              	 
      	
                TITLE

              

      

    

     

     

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
    

     

    
      	 Amarin
      Neuroscience	 	
               CONFIDENTIAL

            	 	
               Change Order
      No. 2

            
	
               

            	 	 	 	
               Version 4, 7th
      of June 2006

            

    

     

    
 

     

    Appendix
1

     

     

    Change
Order No. 2

     

    Europe
Revised Project Specifications and Cost

     

    Document

     

    Version
4, Submitted 7th June 2006

     

    A
MULTICENTRE, MULTINATIONAL, DOUBLE-BLIND, RANDOMISED,

    PARALLEL
GROUP, PLACEBO CONTROLLED TRIAL OF ETHYL-EPA

    (ETHYL-ICOSAPENT)
IN PATIENTS WITH HUNTINGTON’S DISEASE

     

    Protocol
Number: AN01.01.0012

     

    
      
         

      

      
        Page 1 of
18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    
 

    
      	
               

              1.  Introduction

            

    

    

    This
document includes revised specifications to the Clinical Research Proposal
Version 5 Submitted 17 May 2005 and the Change Order #1 document (Version 2,
Dated 15 Nov 2005) and associated costs for the clinical conduct of study
AN01.01.0012 in Europe.  The main changes to the project
specifications are to the study timelines, the site and patient distribution and
the CRF page numbers.  For Biometrics, we have removed the costs for
the US study and the synergies for managing both studies in
parallel.

     

    The study
set-up was delayed primarily due to the late delivery of the final signed
protocol to ICON on the 9th of August.  Study set-up was also delayed
due to the delay in providing details of the required number of pre-selected
sites.  Details of the final 5 sites were provided to ICON on the
14th
of September 2005.

     

    Consequently
the selection of study sites was delayed as well as EC and regulatory
submissions.  The other study timelines will also be affected
accordingly.

     

    It is now
planned to conduct this study in 6 countries.  Austria, Italy and
Portugal have been added to the countries originally selected (other countries
previously agreed are:  Germany, Spain, UK and Netherlands, however
Netherlands has now been excluded).

     

    Allowing
for staggered site initiations, we estimate that the total number of monitoring
visits for each site will vary from 7 to 9 visits.  We propose that
the monitoring frequency from April to August 2006 be every 5
weeks.  This will have an impact on CRA and CPM allocation and these
allocations have been increased accordingly (CPM = 0.8 FTE, CRA = 4.6
FTE).  The increase in CRA allocation has also been due to an increase
in the number of CRF pages from 60 pages to 96 pages.  We have been
able to reduce the planned number of CRAb allocated after study set-up from a
total of 3 FTEs to 2.8 FTEs (January 2006 to March 2006).

     

    In order
to effectively manage the study we have extended the Project Manager to 0.8 FTEs
from the original 1-month after the planned FPI (1st September 2005) until 15
days after, the revised planned FPI (15th December 2005).

     

    Following
the meeting with Amarin on 7th November 2005, it was agreed that as the clinical
resource required will be heavily dependent on enrolment and site activity, and
as the CRF has increased to a 96-page CRF (from 60 pages) ICON will actively
evaluate the clinical resource on an ongoing basis and provide 3-monthly reports
to Amarin of the same.  Where required, ICON will adjust the clinical
resource, following written approval from Amarin.

     

    During a
subsequent meeting with Amarin on 16th February 2006 it was agreed that
additional changes in specifications would be included in Change Order No:
1.

     

     

    

    
      
         

      

      
        Page 2 of
18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

      	
              2.  Revised
      Clinical project Specifications

            

    

    

    (1)           Project
Timelines:

     

    The table
below summarizes the original and revised projected timelines for the conduct of
this study.

     

    
      	
              Milestone

            	
              Original
      Date

            	
              Revised
      Date

            
	
              ICON
      involvement begins

            	
              1st
      April 2005

            	
              1st April
      2005

            
	
              Final
      Protocol Available*

            	
              1st
      June 2005

            	
              9th
      August 2005

            
	
              First
      patient in

            	
              1st
      September 2005

            	
              15th
      December 2005

            
	
              Last
      patient screened

            	
              Not
      specified

            	
              June
      2006

            
	
              Last
      patient in

            	
              1st
      March 2006

            	
              July
      2006

            

    

    

    The
proposed revised dates for LPO, Database lock and ICON end will be according to
previously agreed intervals.

     

    The
revised timelines include the following revisions:

     

    
      	
              ·  

            	
              A
      delay of 2.5 months to study
set-up.

            

    

     

    
      	
              ·  

            	
              The
      inclusion of the 1-month follow-up period (i.e. patients will be in the
      study for 6 months plus 1 month
follow-up)

            

    

     

    
      	
              ·  

            	
              The
      inclusion of an additional 2 weeks period (It was planned to screen the
      first patient in December 2005; in the project meeting in November it was
      decided that the last patient in date would be June 2006, in total 6.5
      months).

            

    

     

    
      	
              ·  

            	
              Last
      patient in date means date last patient randomised to
      medication

            

    

     

    
      	
              ·  

            	
              Last
      patient out date is 1 month/35 days after last patient off
      treatment.

            

    

     

     

    (2)           Site
and Patient Distribution

     

    Approximately
37 sites will be contacted and surveyed to establish their interest and
suitability for participating in this study (originally 38
planned).  It is planned to conduct a total of 37 pre-study visits
(originally 33 planned) and to initiate 30 sites (originally 30
planned).

     

    
      
         

      

      
        Page 3 of
18

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    The
tables below show the site and patient distribution per the original contract as
well as the current site and patient distribution.

     

    Original
Site and Patient Distribution

     

    
      	
              Country

            	
              Number
      of

              screened

              sites

            	
              Number
      of

              initiated
      sites

            	
              Number
      of

              randomized

              patients

            
	
              Germany

            	
              14

            	
              12

            	
              96

            
	
              Netherlands

            
	
              UK

            	
              24

            	
              18

            	
              144

            
	
              Spain

            
	
              TOTAL

            	
              38

            	
              30

            	
              240

            

    

    

     

    Revised
Site and Patient Distribution

     

    
      	
              Country

            	
              Number
      of

              screened

              sites

            	
              Number
      of

              initiated
      sites

            	
              Number
      of

              randomized

              patients

            
	
              Austria

            	
              2

            	
              2

            	
              24

            
	
              Germany

            	
              9

            	
              9

            	
              80

            
	
              Italy

            	
              4

            	
              4

            	
              30

            
	
              Netherlands

            	
              1

            	
              0

            	
              0

            
	
              Portugal

            	
              3

            	
              2

            	
              8

            
	
              Spain

            	
              5

            	
              4

            	
              28

            
	
              Switerland

            	
              1

            	
              0

            	
              0

            
	
              UK

            	
              12

            	
              9

            	
              70

            
	
              TOTAL

            	
              37

            	
              30

            	
              240

            

    

    

    
      
         

      

      
        Page 4 of
18

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

     

    (3)           Staff
Allocation

     

    Based on
the revised study timelines and the current site and patient distribution the
clinical study team allocation has been revised as follows:

     

    
      	
              FTE

            	
              Staff

            	
              Time
      Allocation

            
	
              0.4

            	
              Project
      Manager

            	
              Allocated
      in April 2005

            
	
              0.8

            	
              Project
      Manager

            	
              Allocated
      from 1st  of
      May 2005 through 31st of December 2005

            
	
              0.6

            	
              Project
      Manager

            	
              Allocated
      from 1st of January 2006 through 31st of March 2006

            
	
              0.8

            	
              Project
      Manager

            	
              Allocated
      from 1st of April 2006 through 31st of August 2006

            
	
              0.6

            	
              Project
      Manager

            	
              Allocated
      from 1st of September 2006 through 31st of January 2007

            
	
              0.8

            	
              Project
      Manager

            	
              Allocated
      from 1st
      of February 2007 through 31st of May 2007

            
	
              1.5

            	
              Clinical
      Research Associate(s)

            	
              Allocated
      in April 2005

            
	
              3.0

            	
              Clinical
      Research Associate(s)

            	
              Allocated
      from 1st of May 2005 through 31st of December 2005

            
	
              2.8

            	
              Clinical
      Research Associate(s)

            	
              Allocated
      from 1st of January 2006 through 31st of March 2006

            
	
              4.6

            	
              Clinical
      Research Associate(s)

            	
              Allocated
      from 1st of April 2006 through 31st of August 2006

            
	
              3.4

            	
              Clinical
      Research Associate(s)

            	
              Allocated
      from 1st of September 2006 through 31st of May 2007

            
	
              0.7

            	
              Clinical
      Research Assistant(s)

            	
              Allocated
      in April 2005

            
	
              1.4

            	
              Clinical
      Research Assistant(s)

            	
              Allocated
      from 1st of May 2005 through 31st of December 2005

            
	
              1.2

            	
              Clinical
      Research Assistant(s)

            	
              Allocated
      from 1st of January 2006 through 31st of March 2006

            
	
              1.4

            	
              Clinical
      Research Assistant(s)

            	
              Allocation
      from 1st of April 2006 through 31st of August 2006

            
	
              1.2

            	
              Clinical
      Research Assistant(s)

            	
              Allocation
      from 1st of September 2006 through 31st of May 2007

            
	 
      	
              Therapeutic
      Director

            	
              Allocated
      for 5 days for study duration

            
	 
      	
              Clinical
      Regulatory Compliance Associate

            	
              Allocated
      for 17 days for study duration

            
	 
      	
              Accounting

              Administrator

            	
              Allocated
      for 69 days for study duration

            

    

    

    

    
      
         

      

      
        Page 5 of
18

        
          

        

      

      
         

      

    

    
 

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    The above
allocations are also based on the participation of 30 sites in the project,
96 CRF pages per patient and on a
5-weekly monitoring
visit frequency from April 2006 to August 2006 and 7-weekly thereafter
(previously 6 weekly) for a total of 7-9 visits per site
(previously 8).  Based on the recruitment rates expected at EU sites,
on-site monitoring activities and the revised number of CRF pages will take
approximately 10 hours
to perform.

     

    ICON will
actively evaluate the clinical resource on an ongoing basis and provide
3-monthly reports to Amarin of the same.  Where required, ICON will
adjust the clinical resource, following written approval from
Amarin.

     

     

    (4)           Clinical
Documentation

     

    The
following changes in project specifications have been made in respect to study
documentation:

     

    
      	
              ·  

            	
              ICON
      will write the Austrian Protocol Amendment required for EC and regulatory
      submissions.

            

    

     

    
      	
              ·  

            	
              ICON
      will organise for the translation of medication instructions through a
      third party vendor.

            

    

     

    
      	
              ·  

            	
              ICON
      will organise for the translation of the study protocol into Spanish
      through a third party vendor.

            

    

     

    
      	
              ·  

            	
              ICON
      will organise for the translation of regulatory documentation through a
      third party vendor.

            

    

     

     

    (5)           Clinical
Activities

     

     

    (a)           Administration
of Investigator Payments

     

    ICON will
be responsible for the administration of investigator payments and hospital and
pharmacy fees, where necessary.  Payments will be made by ICON on a
3-monthly basis.  All payments, which will be agreed in advance, will
be charged to Amarin as “pass-through”.  In addition Amarin will
provide ICON with a float of 30% of the total budget of
investigator fees for the payment of investigator fees to support the agreed up
front payments to sites.

     

     

    (b)           Regulatory
Submissions

     

    ICON will
be responsible for any follow-up or re-submission of regulatory clinical trial
submissions to the relevant authorities in Germany, Spain and the
UK.  Any future request will be documented in a change notification
before documented in a change order.  (Amarin has requested ICON to be
responsible for any new submission or follow-up).

     

    ICON will
complete the AMG form for the German submission and will make the local
regulatory notifications.  ICON has also provided advice to Alison
Bannon (Sub-contractor of Amarin) regarding regulatory submissions for a total
of 8 hours.

     

    
      
         

      

      
        Page 6 of
18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

     

    ICON will
be responsible for making regulatory clinical trial submissions to the relevant
authorities in Austria, Italy (including the Osservatorio web site) and
Portugal.  Amarin will provide draft documentation for the Austrian
and Portuguese submissions.

     

    ICON will
be responsible for any additional notification or submission.

     

    Amarin
will be responsible for responding in a timely way to questions from regulatory
agencies to affect a final outcome.  ICON will assist, as
appropriate

     

     

    (c)           Ethics
Committee Submissions

     

    ICON will
be responsible for preparing 27 local and 6 central ethics committee submissions
in Austria, Germany, Italy, Portugal, Spain and in the UK.  Both
Amarin and ICON will be responsible for responding in a timely manner to
questions raised by ethics committees to affect a final outcome.

     

    
      
         

      

      
        Page 7 of
18

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    
 

    
      	
              3.  Revised
      Biometrics Project Specifications

            

    

    

    The
following changes have been made to the Biometrics costs and
specifications:

     

    
      	
              Data
      Management

            	
              Contract

            	
              CO#1

            	
              Comments

            
	
              US
      Study and Synergies:

            	
              -

            	
              -

            	
              Both
      the costs for the US study and the synergies (for managing both studies in
      parallel) have been removed.

            
	
              Timelines
      (EU study):

            	
              21

            	
              28

            	
              The
      original contract specifications were based on 21 months (from 1 Apr 05 to
      1 Jan 07).  The date for database lock has been moved so the
      timelines have been extended by 5 months thus increasing the costs for the
      following activities:  Project Management, teleconferences and
      the review of monthly central laboratory and ECG transfers.  The
      date for Database lock is estimated to be 4-6 weeks post Last Patient Last
      Visit (LPLV) date.  ICON will make all possible efforts to
      achieve Database Lock as early as possible.

            
	
              Status
      Reports (EU study):

            	
              21

            	
              76

            	
              The
      original contract specifications were based on monthly status reports over
      21 months.  From April 2006 status reports will be provided on a
      weekly basis, thus the number of reports has increased to
    76.

            
	
              Face-to-face
      Meetings (EU study):

            	
              2

            	
              6

            	
              The
      original contract specifications were based on attendance at two
      face-to-face meetings.  Four additional meetings have been
      included (including travel costs) as the Data Management group has already
      attended two meetings to date and it is expected that there will be
      quarterly meetings on an ongoing basis.

            
	
              Pages
      (EU Study):

            	
              13,680

            	
              21,816

            	
              The
      original contract specifications were based on 13,680 (24 drop-outs x 30
      pages plus 216 completers x 60 pages) pages.  The number of CRF
      pages has now increased to 21,816 pages (24 drop-outs x 45 pages plus 216
      completers x 96 pages), thus increasing the costs for data and query
      processing (10%).

            
	
              CRF
      Design (EU study):

            	
              60

            	
              96

            	
              The
      original contract was based on 30 unique/30 replicate CRF
      pages.  This has now increased to 30 unique/66 replicate pages
      thus increasing the costs for CRF
design.

            

    

    

     

    Note:  No changes have
been applied to the Biostatistics costs and specifications as the Statistical
Analysis Plan(s) has yet to be finalised.

     

    
      
         

      

      
        Page 8 of
18

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    
      	
              4.  Revised
      Pass-through Costs

            

    

    

    The
following changes have been made to the cost estimates of pass-through
costs.

     

    
      	
              Activity

            	
              Description

            
	
              Travel
      Costs

            	
              Cost
      estimates for site visits have been increased from an average of £210 to
      £300 due to the revised site allocation.  It is estimated that
      there will be an additional 26 visits conducted.

            
	
              Translations

            	
              Translation
      costs for the following have been included in the
  budget:

            
	 
      	
              Translation
      of patient cards into 7 languages.

            
	 
      	
              Translation
      of medication instructions into 7 languages.

            
	 
      	
              Translation
      of the study protocol into Spanish.

            
	 
      	
              Translation
      of the study synopsis into 3 additional languages.

            
	 
      	
              Translation
      of the informed consent form into 4 additional
  languages.

            
	 
      	
              Translation
      of additional EC documentation for 6 additional
    submissions.

            
	 
      	
              Translation
      of regulatory documents from three languages into
  English.

            
	 
      	
              Translation
      of investigator contracts.

            
	
              Regulatory
      Agency Fees

            	
              Regulatory
      fees for 3 clinical trial submissions have been included in the revised
      pass-through budget.

            
	
              Ethics
      Committee Fees

            	
              EC
      fees for one less EC submission have been deduced from the revised
      pass-through budget.

            
	
              Investigator
      Fees

            	
              Cost
      estimates for investigators fees including hospital overheads and pharmacy
      fees have been included in the revised past-through
  budget.

            

    

    

    
      
         

      

      
        Page 9 of
18

        
          

        

      

      
         

      

    

     

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    
      	
              5.  Revised
      Cost Estimates (Clinical)5.  Revised Cost Estimates
      (Clinical)

            

    

    

    Cost
estimates for ICON services and associated “pass-through” costs are presented in
this section.  These cost estimates reflect the changes in cost
associated with the revised project specifications presented in sections
1-3.  Should these or other project specifications change the cost
estimate provided herein may require modification.

     

    
      	
              Clinical
      Research Management

            	
              Units

            	
              Number
      of

              Units

            	
              Price
      per unit*

            	
              Revised
      Cost

              (STG£)

            	
              Contract

              (STG£)

            	
              Change
      Order (STG£)

            
	
              Therapeutic
      Director

            	
              Days

            	
              5

            	
              1,330

            	
              6,651

            	
              6,651

            	
              0

            
	
              Project
      Manager

            	
              Days

            	
              357

            	
              922

            	
              329,143

            	
              252,780

            	
              76,363

            
	
              Clinical
      Research Associate

            	
              Days

            	
              1663

            	
              497

            	
              827,105

            	
              580,952

            	
              246,153

            
	
              Clinical
      Research Assistant

            	
              Days

            	
              633

            	
              390

            	
              246,579

            	
              197,766

            	
              48,813

            
	
              Clinical
      Regulatory Compliance

            	
              Days

            	
              17

            	
              511

            	
              8,692

            	
              6,977

            	
              1,715

            
	
              Account
      Administrator

            	
              Days

            	
              69

            	
              494

            	
              34,076

            	
              34,076

            	
              0

            
	
              CLINICAL
      RESEARCH MANAGEMENT SUB-TOTAL

            	
              £1,452,246

            	
              £1,079,202

            	
              £373,044

            

    

    

    *Figures
in the “Price per unit” column have been rounded, figures in the “Total” column
are correct.

     

    
      
         

      

      
        Page 10
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    
      	
              Support
      Services

            	
              Units

            	
              Number
      of 
Units

            	
              Price
      per 
unit*

            	
              Revised
      Cost 
(STG£)

            	
              Contract
      
(STG£)

            	
              Change
      Order (STG£)

            
	
              Local
      Ethics Committee Submissions

            	
              Sites

            	
              27

            	
              552

            	
              14,905

            	
              16,562

            	
              -1,657

            
	
              Central
      Ethics Committee Submission

            	
              Sites

            	
              6

            	
              828

            	
              4,968

            	
              3,312

            	
              1,656

            
	
              Regulatory
      Submission

            	
              Submission

            	
              3

            	
              3,005

            	
              9,015

            	
              0

            	
              9,015

            
	
              ICOTrack
      Set-up

            	
              System
      Set-

            	
              1

            	
              2,795

            	
              2,795

            	
              2,795

            	
              0

            
	
              ICOTrackMaintenance

            	
              Months

            	
              26

            	
              177

            	
              4,612

            	
              4,612

            	
              0

            
	
              SUPPORT
      SERVICES SUB-TOTAL

            	
              £36,295

            	
              £27,281

            	
              £9,013

            

    

    

     

    *Figures
in the “Price per unit” column have been rounded, figures in the “Total” column
are correct.

     

    
      	
              ICON
      CLINICAL RESEARCH

            	 
      	 
      	 
      	
              £1,488,541

            	
              £1,106,484

            	
              £382,057

            

    

    

     

    
      
         

      

      
        Page 11
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    

    
      	
              Estimated
      pass-through costs

            	
              Units

            	
              Number
      of

              Units

            	
              Price
      per unit

            	
              Revised
      Cost (STG£)

            	
              Contract
      (STG£)

            	
              Change
      Order

              (STGE)

            
	
              Travel

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Site
      Visit Adjustment

            	
              Visits

            	
              333

            	
              300

            	
              99,900

            	
              69,810

            	
              30,090

            
	
              Additional
      Site visits

            	
              Visit

            	
              26

            	
              300

            	
              7,800

            	
              0

            	
              7,800

            
	
              Team
      Meetings

            	
              Meetings

            	
              7

            	
              629

            	
              4,402

            	
              4,402

            	
              0

            
	
              Sponsor
      Meetings

            	
              Meetings

            	
              7

            	
              1,118

            	
              7,827

            	
              7,827

            	
              0

            
	
              Investigator
      Fees

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Investigator
      Fees

            	
              Patient

            	
              240

            	
              4,900

            	
              1,176,000

            	
              0

            	
              1,176,000

            
	
              Pharmacy
      Fees

            	
              site

            	
              30

            	
              340

            	
              10,200

            	
              0

            	
              10,200

            
	
              Hospital
      Overheads

            	
              10%
      per

            	
              240

            	
              490

            	
              117,600

            	
              0

            	
              117,600

            
	
              Investigator
      Meetings

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Travel

            	
              Attendees

            	
              69

            	
              1,747

            	
              120,543

            	
              120,543

            	
              0

            
	
              Administrative
      Fee - 10%

            	 
      	 
      	 
      	
              12,054

            	
              12,054

            	
              0

            
	
              Translations

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Protocol
      synopsis (1,000 words)

            	
              Language

            	
              6

            	
              391

            	
              2,348

            	
              1,174

            	
              1,174

            
	
              Protocol

            	
              Language

            	
              1

            	
              3,000

            	
              3,000

            	
              0

            	
              3,000

            
	
              Informed
      consent document

            	
              Language

            	
              7

            	
              783

            	
              5,479

            	
              2,348

            	
              3,131

            
	
              EC
      documents

            	
              Submission

            	
              33

            	
              433

            	
              14,297

            	
              11,265

            	
              3,033

            
	
              Medication
      Instructions

            	
              Language

            	
              7

            	
              120

            	
              840

            	
              0

            	
              840

            
	
              Regulatory
      documents

            	
              Submission

            	
              3

            	
              866

            	
              2,598

            	
              0

            	
              2,598

            
	
              Patient
      Cards

            	
              Language

            	
              7

            	
              53

            	
              371

            	
              0

            	
              371

            
	
              Investigator
      Contracts

            	
              Site

            	
              23

            	
              800

            	
              18,400

            	
              0

            	
              18,400

            
	
              Other

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Teleconferencing
      (3 lines)

            	
              Meetings

            	
              65

            	
              84

            	
              5,451

            	
              5,451

            	
              0

            
	
              Ethics
      Committee Fees

            	
              Sites

            	
              33

            	
              559

            	
              18,448

            	
              19,007

            	
              -559

            
	
              Regulatory
      Fees

            	
              Submission

            	
              3

            	
              800

            	
              2,400

            	
              0

            	
              2,400

            
	
              Courier

            	
              per
      site/month

            	
              120

            	
              71

            	
              33,258

            	
              24,710

            	
              8,548

            
	
              Mobile
      phones

            	
              per
      CRA per

            	
              25

            	
              42

            	
              3,675

            	
              2,646

            	
              1,029

            
	 
      	 
      	 
      	 
      	
              £1,666,891

            	
              £281,237

            	
              £1,385,655

            
	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
              CLINICAL
      RESEARCH TOTAL

            	
              £1,488,541

            	
              £1,106,484

            	
              £382,057

            
	
              ESTIMATED
      PASS THROUGH COSTS

            	
              £1,666,891

            	
              £281,237

            	
              £1,385,655

            
	
              OVERALL
      TOTAL

            	
              £3,155,432

            	
              £1,387,720

            	
              £1,763,512

            

    

    

     

    
      
         

      

      
        Page 12
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    

    
      	
              Revised
      cost Estimates (Biometrics)

            

    

     

    

    
      	
              Data
      Management

            	
              Contract
      Costs

            	
              Removal
      of US

              Study
      Costs and

              Synergies

            	
              EU
      Study Cost

              (No
      Synergy)

            	
              New
      Costs

              (CO#1)

            	
              Change
      in

              Specifications

            	
              Cost
      Reduction

            
	
              1.
      Project Management

            	
              £30,677

            	
              £17,367

            	
              £13,310

            	
              £29,951

            	
              £16,641

            	
              -£726

            
	
              Planning

            	
              £9,409

            	
              £6,914

            	
              £2,495

            	
              £3,327

            	
              £832

            	
              -£6,082

            
	
              Communications

            	
              £9,409

            	
              £6,914

            	
              £2,495

            	
              £3,327

            	
              £832

            	
              -£6,082

            
	
              Set-up
      of Status Reports

            	
              £992

            	
              £22

            	
              £969

            	
              £969

            	
              £0

            	
              -£22

            
	
              Ongoing
      Status Reports

            	
              £1,884

            	
              £637

            	
              £1,248

            	
              £4,515

            	
              £3,267

            	
              £2,631

            
	
              2.
      Meetings

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Teleconference
      with Sponsor

            	
              £7,651

            	
              £3,612

            	
              £4,039

            	
              £5,385

            	
              £1,346

            	
              -£2,265

            
	
              Kick-off
      Meeting

            	
              £3,328

            	
              £75

            	
              £3,253

            	
              £3,253

            	
              £0

            	
              -£75

            
	
              Face-to-face
      Meetings

            	
              £3,948

            	
              £1,997

            	
              £1,952

            	
              £16,263

            	
              £14,312

            	
              £12,315

            
	
              3.
      Project Set-up

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Data
      Management Plan

            	
              £4,225

            	
              £1,492

            	
              £2,733

            	
              £2,733

            	
              £0

            	
              -£1,492

            
	
              Study
      Specific Procedures

            	
              £5,147

            	
              £1,104

            	
              £4,042

            	
              £4,042

            	
              £0

            	
              -£1,104

            

    

    
      
         

      

      
        Page 13
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    
      	 
      

              Data
      Management

            	 
      

              Contract
      Costs

            	Removal
      of US
Study
      Costs and
Synergies	 
      

              EU
      Study Cost

              (No
      Synergy)

            	 
      

              New
      Costs

              (CO#1)

            	 
      

              Change
      in

              Specifications

            	 
      

              Cost
      Reduction

            
	
              Edit
      Check Document

            	
              £6,659

            	
              £1,906

            	
              £4,753

            	
              £4,753

            	
              £0

            	
              -£1,906

            
	
              Data
      Management Report

            	
              £3,026

            	
              £649

            	
              £2,376

            	
              £2,376

            	
              £0

            	
              -£649

            
	
              Database
      Setup

            	
              £14,839

            	
              £1,628

            	
              £13,211

            	
              £13,211

            	
              £0

            	
              -£1,628

            
	
              Edit
      Programming

            	
              £28,107

            	
              £8,046

            	
              £20,061

            	
              £20,061

            	
              £0

            	
              -£8,046

            
	
              Data
      Listings - Programming

            	
              £3,026

            	
              £649

            	
              £2,376

            	
              £2,376

            	
              £0

            	
              -£649

            
	
              Central
      Laboratory - Programming

            	
              £4,886

            	
              £1,678

            	
              £3,208

            	
              £3,208

            	
              £0

            	
              -£1,678

            
	
              ECG
      - Programming

            	
              £6,491

            	
              £3,282

            	
              £3,208

            	
              £3,208

            	
              £0

            	
              -£3,282

            
	
              4.
      Review External Data

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Central
      Laboratory - Data

              Reconciliation

            	
              £11,745

            	
              £7,067

            	
              £4,679

            	
              £6,238

            	
              £1,560

            	
              -£5,507

            
	
              ECG
      - data Reconciliation

            	
              £5,873

            	
              £3,533

            	
              £2,339

            	
              £3,119

            	
              £780

            	
              -£2,754

            
	
              5.
      Data Processing

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              CRF
      Scanning

            	
              £20,269

            	
              £11,264

            	
              £9,005

            	
              £13,772

            	
              £4,766

            	
              -£6,498

            
	
              Data
      Entry

            	
              £58,239

            	
              £32,685

            	
              £25,555

            	
              £40,753

            	
              £15,198

            	
              -£17,486

            
	
              Obvious
      Corrections

            	
              £42,736

            	
              £23,984

            	
              £18,752

            	
              £29,905

            	
              £11,153

            	
              -£12,831

            
	
              Data
      Listings - Review

            	
              £5,001

            	
              £2,807

            	
              £2,194

            	
              £3,499

            	
              £1,305

            	
              -£1,502

            
	
              Validation

            	
              £60,777

            	
              £34,109

            	
              £26,668

            	
              £42,529

            	
              £15,861

            	
              -£18,248

            

    

    
      
         

      

      
        Page 14
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    

    
      	 
      

              Data
      Management

            	 
      

              Contract
      Costs

            	
              Removal of US
Study
      Costs and
Synergies

            	 
      

              EU
      Study Cost

              (No
      Synergy)

            	 
      

              New
      Costs

              (CO#1)

            	 
      

              Change
      in

              Specifications

            	 
      

              Cost
      Reduction

            
	
              6.
      Coding

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Data
      Coding (60% autoencode)

            	
              £9,228

            	
              £5,179

            	
              £4,049

            	
              £4,049

            	
              £0

            	
              -£5,179

            
	
              7.
      Query Processing

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Query
      Resolution

            	
              £28,864

            	
              £16,199

            	
              £12,665

            	
              £20,198

            	
              £7,532

            	
              -£8,666

            
	
              8.
      Data Transfers to Sponsor

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              Test
      Transfer

            	
              £2,449

            	
              £1,176

            	
              £1,274

            	
              £1,274

            	
              £0

            	
              -£1,176

            
	
              Final
      Database Transfer

            	
              £12,625

            	
              £5,981

            	
              £6,644

            	
              £6,644

            	
              £0

            	
              -£5,981

            
	
              9.
      Closeout Activities

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              CRF
      Quality Control Reviews (SQRT n+1) Enrolled Patients

            	
              £1,483

            	
              £791

            	
              £692

            	
              £692

            	
              £0

            	
              -£791

            
	
              Critical
      Item Reviews 100% Enrolled Patients

            	
              £12,796

            	
              £8,411

            	
              £4,384

            	
              £4,384

            	
              £0

            	
              -£8,411

            
	
              Closeout
      & Archive

            	
              £4,893

            	
              £2,648

            	
              £2,246

            	
              £2,246

            	
              £0

            	
              -£2,648

            
	
              10.
      SAE Reconciliation

            	 
      	 
      	 
      	 
      	 
      	 
      
	
              SAE
      Reconciliation

            	
              £5,741

            	
              £3,313

            	
              £2,428

            	
              £2,428

            	
              £0

            	
              -£3,313

            
	
              DATA
      MANAGEMENT*

            	
              £426,423

            	
              £217,119

            	
              £209,304

            	
              £304,688

            	
              £95,384

            	
              -£121,734

            

    

     

    *NOTE:  No costs have
been included for the merging of data between the EU and US studies, which, if
requested, may incur an additional cost.

    
 

    
      	
              CFR
      DESIGN

            	
              £16,393

            	
              £3,279

            	
              £13,114

            	
              £15,906

            	
              £2,791

            	
              -£487

            

    

     

    

    
      	
              BIOSTATISTICS

            	
              £163,451

            	
              -

            	
              -

            	
              £163,451

            	
              -

            	
              -

            

    

     

    

    
      	
              PASS-THROUGH
      COSTS

            	
              £50,742

            	
              £26,972

            	
              £23,770

            	
              £34,019

            	
              £10,249

            	
              £16,723

            

    

    

     

    

    
      
         

      

      
        Page 15
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      Neuroscience	 	
                 CONFIDENTIAL

              	 	
                 Change Order
      No. 2

              
	
                 

              	 	 	 	
                 Version 4, 7th
      of June 2006

              

      

       

    

    The table
below summarizes the revised, original and change order cost.

     

    
      	
              Overall
      costs

            	
              Revised
      Cost 

              
(STG£)

            	
              Contract
      Costs

              
 (STG£)

            	
              Change
      Order 

              
(STG£)

            
	
              CLINICAL
      RESEARCH TOTAL

            	
              1,488,541

            	
              1,106,484

            	
              382,057

            
	
              ESTIMATED
      PASS THROUGH COSTS

            	
              1,666,891

            	
              281,237

            	
              1,385,655

            
	
              OVERALL
      CLINICAL TOTAL

            	
              £3,155,432

            	
              £1,387,720

            	
              £1,763,512

            
	 
      	 
      	 
      	 
      
	
              DATA
      MANAGEMENT

            	
              304,688

            	
              426,423

            	
              -121,734

            
	
              CRF
      DESIGN

            	
              15,906

            	
              16,393

            	
              -487

            
	
              BIOSTATISTICS

            	
              163,451

            	
              163,451

            	
              0

            
	
              DM
      and BIOSTAT PASS-THROUGH Costs

            	
              34,019

            	
              50,742

            	
              -16,723

            
	
              OVERALL
      DM and BIOSTAT TOTAL

            	
              £518,064

            	
              £657,009

            	
              -£138,944

            
	 
      	 
      	 
      	 
      
	
              OVERALL
      TOTAL

            	
              £3,673,496

            	
              £2,044,729

            	
              £1,624,568

            

    

    

    

     

    
      
         

      

      
        Page 16
of 18

        
          

        

      

      
         

      

    

     

    
       

      
        	 Amarin
      694/005	 	
                 

              	 	
                 

              
	 	 	 	 	 
	 Protocol
      AN01.01.0012	 	 	 	
                 Change Order No.
      2  Version 4, 7th
      of June 2006

              
	
                 

              	 	 	 	
                Payment
      Schedule

              

      

       

    

     

    Payment
Schedule

     

    
      	
              Summary
      of Costs (CO#2)

            

    

    

    
      	
              Change
      Order Direct Fee Value:  £382,057

            
	
              Initial
      Payment 10% on signature of Change Order (June 06)

            	
              £38,205

            
	
              Monthly
      Payments x 12 months (June ’06 to May ’07)

              £28,654.33
      per month

            	
              £343,852

            

    

    

    
      	
              Change
      Order Direct Fee Value:  -£122,221

            
	
              Initial
      Payment 10% on signature of Change Order (June 06)

            	
              -£12,222

            
	
              Monthly
      Payments x 12 months (June ’06 to May ’07) -

              £1,018.51
      per month

            	
              £109,999

            

    

    

    
      	
              SUMMARY:  Change
      Order 2 Payment Schedule

            
	
              Change
      Order Direct Fee Value:  Clinical

            	
              £382,057

            
	
              Change
      Order Direct Fee Value:  Data Management

            	
              -£122,221

            
	 
      	
              £259,836

            

    

    

     

    
      	
              Summary
      of Costs (CO#2)

            

    

    

    
      	
              10%
      upon signature

            	
              £25,984

            
	
              Monthly
      Payments x 12 months (June ’06 to May ’07)

            
	
              £19,487.70
      per month

            	
              £233,852

            
	 
      	
              £259,836

            

    

    

    
      	
              REVISED
      ICON EU PAYMENT SCHEDULED (CHANGE ORDER #2)U PAYMENT SCHEDULED (CHANGE
      ORDER #2)

            
	 
      	 
      
	
              Milestone
      Payments

            	 
      
	
              Task
      Completed

            	
              Contract
      Value

            
	
              Contract
      Signed

            	
              342,550

            
	
              All
      sites initiated

            	
              192,684

            
	
              50%
      of patients enrolled

            	
              192,684

            
	
              Initial
      Payment 10% on signature of C/O#2

            	
              25,984

            
	
              100%
      of patients enrolled

            	
              192,684

            
	
              Mid-point
      of treatment phase

            	
              192,684

            
	
              All
      patients completed and data at DM

            	
              192,684

            
	
              All
      sites closed

            	
              38,537

            
	
              Final
      Tables & Listings

            	
              25,691

            

    

    

    
      	
              Total
      Milestones payments

            	
              £1,396,185

            
	
              Monthly
      Payments contract

            	
              April
      ’05 - June ‘07

            	
              22

            	
              15,570

            	
              342,550

            
	
              Monthly
      Payments change order #2*

            	
              Jun
      ’06 - May ‘07

            	
              12

            	
              19,488

            	
              233,852

            

    

    

    
      	
              Total
      Monthly payments

            	
              £576,403

            
	 
      	 
      
	
              Total
      payments

            	
              £1,972,587

            

    

    

    *Change
Order #2:  monthly payment have been adjusted to include the increase
of the clinical direct cost and decrease the data management cost

     

    
      
         

      

      
        Page 17
of 18

        
          

        

      

      
         

      

    

     

    
      
         

        
          	 Amarin
      694/005	 	
                   

                	 	
                   

                
	 	 	 	 	 
	 Protocol
      AN01.01.0012	 	 	 	
                   Change Order No.
      2  Version 4, 7th
      of June 2006

                
	
                   

                	 	 	 	
                  Payment
      Schedule

                

        

         

      

    IN WITNESS WHEREOF, the
parties hereto have executed this Change Order by their duly authorised
representatives on the date(s) written below.

     

    

    
      	
              Amarin
      Neuroscience Limited

            	
              ICON
      Clinical Research Limited

            
	
              King’s
      Park House

            	
              South
      County Business Park

            
	
              Laurelhill
      Business Park

            	
              Leopardstown

            
	
              UKFK7
      9PQ

            	
              Dublin
      18

            
	
              United
      Kingdom

            	
              Ireland

            

    

    

    
      
 

      
        
          	 16
      October 2006	 	 29
      September 2006
	
                  DATE

                	 
      	
                  DATE

                
	 	 	 
	 /s/
      Anthony Clarke	 	 /s/
      Sean Leech
	
                  SIGNED

                	 
      	
                  SIGNED

                
	 	 	 
	 A.
      CLARKE	 	 SEAN
      LEECH
	
                  NAME

                	 
      	
                  NAME

                
	 	 	 
	
                   

                  VP CLINICAL DEVELOPMENT

                	 	 EXEC.
      VP COMMERCIAL AND ORGANISATIONAL DEVELOPMENT
	
                  TITLE

                	 
      	
                  TITLE

                

        

      

       

       

       

       

      Page 18 of 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]